Komori
Immuno-Biological Laboratories (4570) · PolicyFirst stated

Review of the write-down treatment for the book value of newly acquired fixed assets

First written in FY2024. . Latest entry: FY2024.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Review of the treatment of writing down the carrying amount of newly acquired fixed assets at acquisitionA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2024First statedAnnual report

    「For fixed assets acquired through the previous fiscal year, we had recognised the entire amount as an expense by writing down their carrying value. From the current fiscal year, however, we determined that a full write-down of carrying value is no longer necessary.」

    The Company reviewed, from the current fiscal year, the practice of fully writing down the carrying value of fixed assets at acquisition, which was one factor contributing to the recognition of operating income of ¥104.299 million.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Immuno-Biological Laboratories yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Review of the write-down treatment for the book value of newly acquired fixed assets | Immuno-Biological Laboratories Co.,Ltd. (4570) | Komori